NUVB

Nuvation Bio Inc. is a biotechnology company within the healthcare sector. With a market capitalization of $2.94B and revenue of $26.75M, it operates on a relatively large scale compared to its industry peers. The company's financial health is marked by significant net losses, with a net income of -$217,480,000 over the trailing twelve months. Its profitability metrics are also concerning, with an operating margin of -430.1% and a profit margin of 0.0%. However, it has a gross margin of 54.3%, indicating that it is able to maintain some level of pricing power for its products or services. The company's balance sheet shows a cash position of $549.04M against debt of $57.55M, resulting in a debt-to-equity ratio of 17.66. Nuvation Bio Inc.'s valuation metrics are notable due to its negative forward P/E ratio and EV/EBITDA, indicating significant losses and declining value. The company's revenue growth over the past year has been substantial at 1704.7%, but earnings growth is not available for comparison. Its dividend yield is not applicable as it does not pay a dividend.